Printer Friendly

Browse Biological products industry topic

Product development subtopic

 

Articles

1-300 out of 500 article(s) nextnext page
Title Author Type Date Words
BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy Collaboration. Oct 18, 2017 1268
Sutro Marks Two Drug Development Milestones. Oct 11, 2017 686
Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer. Oct 10, 2017 1310
Japan : Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Oct 4, 2017 633
United States : Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens. Clinical report Oct 4, 2017 326
Pharming Group share data from phase II clinical data for RUCONEST. Oct 2, 2017 217
Pharming Announces Positive Data From Paediatric Clinical Trial With RUCONEST. Oct 2, 2017 1782
Pharming reports safe data from RUCONEST clinical trial in children with hereditary angioedema. Oct 2, 2017 282
Pharming reports safe data from RUCONEST clinical trial in children with hereditary angioedema. Oct 2, 2017 278
Pharming Announces Positive Data from Paediatric Clinical Trial with RUCONEST. Sep 29, 2017 1758
Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for Varicella Vaccine Candidate Against Chickenpox. Sep 25, 2017 934
Enteris BioPharma doses first woman under Phase 2a clinical trial of Ovarest for treating endometriosis. Aug 25, 2017 268
Enteris BioPharma doses first woman under Phase 2a clinical trial of Ovarest for treating endometriosis. Aug 25, 2017 264
Enteris BioPharma Initiates Phase 2a Clinical Trial of Ovarest (oral leuprolide tablet) for Endometriosis. Aug 25, 2017 261
Enteris BioPharma Doses First Woman in Phase 2a Clinical Trial of Ovarest(TM) (oral leuprolide tablet) for Endometriosis. Aug 24, 2017 729
CEL-SCI Receives Permission from FDA to Resume Phase 3 Head and Neck Cancer Trial. Aug 15, 2017 263
Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis. Aug 8, 2017 2169
CTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI for Aggressive B-cell non-Hodgkin lymphoma. Aug 2, 2017 1028
Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis. Clinical report Aug 2, 2017 2482
CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib. Aug 1, 2017 714
CTI BioPharma Corp enrols first patient in Phase two clinical trial of pacritinib. Aug 1, 2017 137
RegeneRx Updates on RGN-259 Phase 3 Dry Eye Trial. Jul 27, 2017 853
Bio Products Laboratory Presents New Phase 3 Data Demonstrating Prophylactic Coagadex (Coagulation Factor X, Human) Dosing Prevents or Reduces Bleeding Episodes in Children with Moderate to Severe Hereditary Factor X Deficiency. Clinical report Jul 12, 2017 1489
ThromboGenics and BioInvent Amending Long-standing Monoclonal Antibody Development Agreement. Jul 10, 2017 995
ThromboGenics and BioInvent Amending Long-standing Monoclonal Antibody Development Agreement. Jul 10, 2017 999
BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration. Jul 10, 2017 1291
Galapagos NV announces new Phase 2 study for filgotinib. Clinical report Jul 5, 2017 198
Galapagos NV announces new Phase 2 study for filgotinib. Clinical report Jul 5, 2017 194
GSK meets primary objective in phase three revaccination trial of Shingrix. Jun 23, 2017 205
RedHill Biopharma announces positive top-line results from Phase III GUARD study with BEKINDA. Clinical report Jun 14, 2017 258
RedHill Biopharma announces positive top-line results from Phase III GUARD study with BEKINDA. Clinical report Jun 14, 2017 254
Japan : Takeda and Seattle Genetics Announce Lancet Publication of Phase 3 ALCANZA Clinical Trial Data of ADCETRIS (Brentuximab Vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma. Jun 10, 2017 420
Astellas and Seattle Genetics Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer at 2017 ASCO Annual Meeting. Jun 5, 2017 1720
BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors. Jun 1, 2017 1187
Gilead Touts Positive Phase 3 Data on Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV-1. May 31, 2017 213
Ireland,United Kingdom : Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS. May 24, 2017 338
Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS. Report May 23, 2017 3240
Kemwell Biopharma supplies biologics drug substance to US customer for Phase 1 clinical trials. May 18, 2017 173
Kemwell Biopharma supplies biologics drug substance to US customer for Phase 1 clinical trials. May 18, 2017 169
Kemwell Biopharma Supplies Biologics Drug Substance for Phase 1 Clinical Trials for US IND Filing. May 17, 2017 392
Array BioPharma signs clinical trial collaboration agreement with Merck. May 11, 2017 211
Array BioPharma signs clinical trial collaboration agreement with Merck. May 11, 2017 207
RegeneRx JV Presents Results of Phase 2b/3 (ARISE-1) Dry Eye Trial at ARVO 2017. May 9, 2017 1220
PaxVax Initiates Clinical Trials of a Modernized Adenovirus Vaccine in Collaboration with the U.S. Army Medical Materiel Development Activity and the Walter Reed Army Institute of Research to Protect U.S. Military Personnel. May 8, 2017 1002
Yisheng Biopharma Starts Enrollment in Phase 1 Immuno-Oncology Clinical Trial of YS-ON-001 in Patients with Advanced Solid Tumors. May 1, 2017 570
Biotime forms subsidiary to develop programs focused on aging. Apr 17, 2017 238
Biotime forms subsidiary to develop programs focused on aging. Apr 17, 2017 237
Galapagos to complete three new Phase 2 proof-of-concept studies with filgotinib. Apr 4, 2017 212
Galapagos to complete three new Phase 2 proof-of-concept studies with filgotinib. Apr 4, 2017 208
Genentech to begin second Phase 3 trial for Alzheimer's therapy. Apr 1, 2017 111
Paradigm Biopharmaceuticals sees success in hay fever clinical trials. Mar 23, 2017 237
Paradigm Biopharmaceuticals sees success in hay fever clinical trials. Mar 23, 2017 233
Roche's Genentech to begin new Phase III trial of Alzheimer's drug. Mar 1, 2017 271
Roche's Genentech to begin new Phase III trial of Alzheimer's drug. Mar 1, 2017 267
Bird flu vaccines poised to start clinical trials in China. Feb 20, 2017 295
Bird flu vaccines poised to start clinical trials in China. Feb 20, 2017 291
US FDA grants Qualified Infectious Disease Product fast-track designation to RedHill Biopharma's RHB-104. Jan 16, 2017 170
US FDA grants Qualified Infectious Disease Product fast-track designation to RedHill Biopharma's RHB-104. Jan 16, 2017 174
MorphoSys' partner Novartis to start Phase 2 trial with Bimagrumab in obese type 2 diabetes patients. Jan 12, 2017 176
MorphoSys' partner Novartis to start Phase 2 trial with Bimagrumab in obese type 2 diabetes patients. Jan 12, 2017 172
Seattle Genetics enrols first patient in multicentre phase 1 clinical trial of SGN-CD352A. Jan 9, 2017 174
Seattle Genetics enrols first patient in multicentre phase 1 clinical trial of SGN-CD352A. Jan 9, 2017 170
Galena Biopharma confirms the 505(b)(2) regulatory pathway for Phase 3 clinical trial design of GALE-401 for essential thrombocythemia. Dec 29, 2016 310
Galena Biopharma confirms the 505(b)(2) regulatory pathway for Phase 3 clinical trial design of GALE-401 for essential thrombocythemia. Dec 29, 2016 306
CTI BioPharma Announces Phase 3 Data from the PERSIST-2 Trial of Pacritinib to be Presented in Late-Breaking Session at ASH Annual Meeting. Nov 21, 2016 1755
FDA Grants Fast Track Designation for Development of E2609, Eisai's BACE Inhibitor for Early Alzheimer's Disease. Nov 17, 2016 1039
United States : Gilead announces Top-Line Results From Two Phase 3 Studies Evaluating Momelotinib for Patients With Myelofibrosis. Clinical report Nov 17, 2016 409
United States : Catalent expert to present on clinical trial supply strategies for small and mid-size biopharma sponsors. Nov 14, 2016 307
Pharming Announces the Presentation of the Results of the RUCONEST Phase II Study for Prophylaxis of Hereditary Angioedema Attacks. Nov 14, 2016 1463
RegeneRx Biopharmaceuticals enrols first patients in ARISE-2 trial of RGN-259. Nov 11, 2016 234
RegeneRx Biopharmaceuticals enrols first patients in ARISE-2 trial of RGN-259. Nov 11, 2016 230
United States : Janssen Announces Clinical Trial Collaboration and Supply Agreement with Amgen to Evaluate daratumumab (DARZALEX) in Combination with carfilzo0mib. Nov 11, 2016 626
RegeneRx admits first patients in Phase 3 US dry eye clinical trial with RGN-259. Nov 10, 2016 303
RegeneRx admits first patients in Phase 3 US dry eye clinical trial with RGN-259. Nov 10, 2016 299
Janssen Announces Clinical Trial Collaboration and Supply Agreement with Amgen to Evaluate daratumumab (DARZALEX) in Combination with carfilzomib (KYPROLIS). Nov 10, 2016 2643
United States : Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS in Frontline Mature T-cell Lymphoma. Nov 9, 2016 574
Japan : Seattle Genetics and Takeda complete enrollment of phase 3 ECHELON-2 clinical trial evaluating ADCETRIS (Brentuximab Vedotin) in frontline mature T-cell Lymphoma. Nov 9, 2016 578
RegeneRx Announces First Patients Enrolled in Phase 3 U.S. Dry Eye Clinical Trial (ARISE-2 Trial) with RGN-259. Nov 9, 2016 1435
First data from dry-AMD trial to be presented in December. Nov 7, 2016 412
Mereo BioPharma's acumapimod reports positive results for Phase one drug interaction study. Report Nov 7, 2016 117
Mereo BioPharma's acumapimod reports positive results for Phase one drug interaction study. Report Nov 7, 2016 113
Bremelanotide Meets Co-Primary Endpoints in Palatin's Phase 3 Trials for Hypoactive Sexual Desire Disorder. Nov 1, 2016 1680
First data from dry-AMD trial to be presented in December. Oct 31, 2016 412
First data from Dry-AMD trial to be presented in December. Oct 31, 2016 412
Novogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma. Oct 30, 2016 888
Novogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma. Oct 30, 2016 851
Theravance Biopharma Announces Positive Results Including Biomarker Data from Phase 1 Multiple-Ascending Dose Study of TD-0714, an Inhibitor of Neprilysin (NEP). Oct 25, 2016 1841
Array BioPharma And Pierre Fabre To Present Phase 3 COLUMBUS Trial At Society For Melanoma Research Annual Congress. Oct 25, 2016 1732
United States : Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy (FTC/TAF)-Based Regimens from Truvada (FTC/TDF)-Based Regimens. Oct 25, 2016 310
Theravance Biopharma's and Mylan's jointly developed revefenacin drug indicates benefits in phase three trials. Oct 24, 2016 208
Theravance Biopharma's and Mylan's jointly developed revefenacin drug indicates benefits in phase three trials. Oct 24, 2016 204
United States : Theravance biopharma and Mylan announce positive results from two pivotal phase 3 studies of revefenacin (td-4208) for the treatment of chronic obstructive pulmonary disease (copd). Oct 21, 2016 323
United States : Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD). Financial report Oct 21, 2016 340
Theravance Biopharma and Mylan Announce Positive Results from Two Pivotal Phase 3 Studies of Revefenacin (TD-4208) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD). Oct 20, 2016 3057
Theravance Biopharma and Mylan Announce Positive Results from Two Pivotal Phase 3 Studies of Revefenacin (TD-4208) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD). Oct 20, 2016 3105
Sinovac Product Pipeline News. Oct 19, 2016 940
First Ever Human Trial of a Live Attenuated Functioning Therapeutic Herpes Vaccine. Oct 17, 2016 915
Theravance Biopharma doses first patient in Phase 1b clinical trial of TD-1473. Oct 6, 2016 228
Theravance Biopharma doses first patient in Phase 1b clinical trial of TD-1473. Oct 6, 2016 224
RegeneRx Joint Venture Initiates Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome. Sep 30, 2016 833
DS Biopharma Will Today Present Data on a Phase IIa Study at the European Academy of Dermatology and Venereology (EADV) Congress. Sep 29, 2016 239
Array BioPharma and Pierre Fabre Announce COLUMBUS Phase 3 Study of Encorafenib plus Binimetinib For BRAF-Mutant Melanoma Met Primary Endpoint. Sep 26, 2016 2268
Novavax fails to meet phase three trial objectives in RSV F-protein recombinant nanoparticle vaccine. Sep 19, 2016 247
Novavax fails to meet phase three trial objectives in RSV F-protein recombinant nanoparticle vaccine. Sep 19, 2016 243
Enteris BioPharma's "Feasibility to Licensing" Partner, Cara Therapeutics, Advances Peptelligence(TM)-Engineered CR845 into Phase 2b Clinical Trial in Chronic Pain. Sep 19, 2016 848
LEUKOCARE Grants License to US Vaccine Company PaxVax. Sep 13, 2016 505
LEUKOCARE Grants License to US Vaccine Company PaxVax. Sep 13, 2016 510
Immunovaccine treats first recurrent ovarian cancer patient under Phase 1b clinical trial triple combination study. Sep 9, 2016 313
Immunovaccine treats first recurrent ovarian cancer patient under Phase 1b clinical trial triple combination study. Sep 9, 2016 309
Array BioPharma submits NDA for binimetinib with the US FDA for advanced NRAS-mutant melanoma. Sep 2, 2016 314
Array BioPharma submits NDA for binimetinib with the US FDA for advanced NRAS-mutant melanoma. Sep 2, 2016 310
Biogen and Ionis Pharmaceuticals Phase III trial evaluating nusinersen in infantile-onset (consistent with Type 1) spinal muscular atrophy (SMA), met the primary endpoint pre-specified for the interim analysis. Sep 1, 2016 155
United States : CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis. Aug 30, 2016 168
Palatin Technologies reports last HSDD patient visit under Phase 3 clinical trials of bremelanotide. Aug 5, 2016 232
Palatin Technologies reports last HSDD patient visit under Phase 3 clinical trials of bremelanotide. Aug 5, 2016 228
Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder. Aug 4, 2016 846
VM BioPharma Announces Korea Food and Drug Administration Approval of Phase 2 Clinical Trial for Investigational Gene Therapy VM202 in Ischemic Heart Disease. Aug 2, 2016 1450
Japan : Takeda and Seattle Genetics announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma. Aug 2, 2016 191
Japan,United States : Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma. Aug 2, 2016 189
LSK BioPharma Announces Successful Outcome from End-of-Phase 2 meeting with FDA. Jul 26, 2016 548
CSL Behring Presents Phase III Data for IDELVION for Hemophilia B at the World Federation of Hemophilia 2016 World Congress. Jul 26, 2016 2087
Japan,United States : Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood. Jul 19, 2016 439
Japan : Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood. Jul 19, 2016 498
Array BioPharma submits first NDA for binimetinib for treating melanoma. Jul 1, 2016 265
Second patient cohort approved in clinical trial for dry AMD. Jun 20, 2016 342
Theravance Biopharma's Phase 1 clinical trial of TD-1473 reveals positive results. Jun 13, 2016 200
Theravance Biopharma's Phase 1 clinical trial of TD-1473 reveals positive results. Jun 13, 2016 196
DSMB approves second patient cohort in clinical trial for dry AMD. Jun 13, 2016 343
DSMB approves second patient cohort in clinical trial for dry AMD. Jun 13, 2016 344
Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting. Jun 6, 2016 2208
Merck Partners with Array BioPharma and Pierre Fabre to Initiate BRAF-mutant CRC Phase III Trial. Jun 4, 2016 1699
Array BioPharma, Pierre Fabre and Merck KGaA, Darmstadt, Germany Announce Phase 3 BEACON CRC Trial. Jun 4, 2016 2181
Merck Partners with Array BioPharma and Pierre Fabre to Initiate BRAF-mutant CRC Phase III Trial. Jun 4, 2016 1695
Astellas and Medivation Initiate Phase III Trial of Enzalutamide in Patients with Triple-Negative Breast Cancer. Jun 2, 2016 2142
Qiagen signs licensing and co-development agreement with Therawis Diagnostics. May 26, 2016 171
Qiagen signs licensing and co-development agreement with Therawis Diagnostics. May 26, 2016 167
One year Cohort I data from Phase 2 Pathway SCI study. Clinical report May 16, 2016 211
One year Cohort I data from Phase 2 Pathway SCI Study. Clinical report May 16, 2016 211
RGN-259 Confirms Efficacy in Signs and Symptoms of Dry Eye. May 6, 2016 1824
Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma. May 2, 2016 1211
Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma. May 2, 2016 1206
Preclinical Data Presented At AACR Indicate Pacritinib's Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment. Apr 20, 2016 1417
Positive interim results from Phase 2 study in spinal cord injury. Apr 18, 2016 437
Positive interim results from phase 2 study in spinal cord injury. Apr 18, 2016 437
BioInvent announces readiness to commence multiple myeloma Phase II study of antibody BI-505. Report Apr 18, 2016 314
BioInvent announces readiness to commence multiple myeloma Phase II study of antibody BI-505. Report Apr 18, 2016 310
Guardant Health Announces Collaboration With Principia Biopharma To Use Guardant360 for Monitoring Patient Response and Tumor Evolution in FGFR Inhibitor Trials. Mar 29, 2016 506
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer. Mar 24, 2016 1975
Regen BioPharma, Inc. Submits IND Application to FDA on tCellVax, a Checkpoint Inhibitor for Cancer Therapy. Mar 23, 2016 653
Biocept to Collaborate on Biopharma Company Clinical Trial by Identifying Biomarkers Found in Cerebral Spinal Fluid for Patients with Lung Cancer that has Spread to the Brain. Mar 21, 2016 1077
Global Cancer Vaccines Clinical Pipeline 2015 by Phase, Indication, Company & Country. Mar 1, 2016 1631
Global Cancer Vaccines Clinical Pipeline 2015 by Phase, Indication, Company & Country. Mar 1, 2016 1671
Seattle Genetics commences phase one clinical trial of B-cell non-Hodgkin lymphoma treatment. Feb 29, 2016 156
Seattle Genetics commences phase one clinical trial of B-cell non-Hodgkin lymphoma treatment. Feb 29, 2016 152
Seattle Genetics commences vadastuximab talirine clinical trials. Feb 24, 2016 204
Seattle Genetics commences vadastuximab talirine clinical trials. Feb 24, 2016 200
CTI BioPharma Provides Update On Investigational Agent Pacritinib. Clinical report Feb 8, 2016 1046
RegeneRx Announces Completion of Patient Enrollment In Phase 2b/3 U.S. Dry Eye Trial. Jan 29, 2016 1089
Journal of Clinical Oncology Publishes Results from the STRIVE trial of enzalutamide Compared to bicalutamide in Castration-resistant Prostate Cancer. Jan 26, 2016 1780
AVAX Technologies Announces Results Of Its OVAX, Ovarian Cancer Vaccine, Phase 1/2 Clinical Trial In Patients With Relapsed Stage III Or IV Ovarian Cancer. Financial report Jan 26, 2016 1127
Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial. Jan 19, 2016 1306
Gilead Sciences submits NDA for tenofovir alafenamide to US FDA for treating chronic hepatitis B virus. Jan 13, 2016 268
Gilead Sciences submits NDA for tenofovir alafenamide to US FDA for treating chronic hepatitis B virus. Jan 13, 2016 264
Lancet Oncology Publishes Results from the Phase 2 TERRAIN Trial of enzalutamide Compared to bicalutamide in Metastatic Castration-Resistant Prostate Cancer. Jan 13, 2016 1751
Ionis Pharmaceuticals Completes Target Enrollment for Nusinersen Phase 3 Study, CHERISH, in Children with Spinal Muscular Atrophy. Jan 12, 2016 2014
Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval of Probuphine, First 6-Month Implant to Treat Opioid Addiction. Jan 12, 2016 1636
DS Biopharma Announces Positive Top-line Phase IIa Trial Results for DS107 as an Oral Treatment for Moderate to Severe Atopic Dermatitis. Clinical report Jan 7, 2016 585
Yisheng Biopharma announces results from Phase I clinical trial of PIKA rabies vaccine. Jan 5, 2016 171
Yisheng Biopharma announces results from Phase I clinical trial of PIKA rabies vaccine. Jan 5, 2016 167
Seattle Genetics and Bristol-Myers Squibb assess Adcetris in combination with Opdivo with commencement of new trial. Dec 24, 2015 201
Seattle Genetics and Bristol-Myers Squibb assess Adcetris in combination with Opdivo with commencement of new trial. Dec 24, 2015 197
DS Biopharma Announces Successful Completion of a Phase I Safety Study With Bioactive Lipid DS102 Which is Targeting NASH and IPF. Dec 18, 2015 376
Novavax commences clinical trial of RSV F Vaccine. Dec 16, 2015 247
Regen BioPharma passes US FDA's clearance to initiate clinical trial of HemaXellerate for treating Aplastic anemia. Dec 16, 2015 227
Novavax commences clinical trial of RSV F Vaccine. Dec 16, 2015 243
Regen BioPharma passes US FDA's clearance to initiate clinical trial of HemaXellerate for treating Aplastic anemia. Dec 16, 2015 223
Array BioPharma Announces Phase 3 Binimetinib Trial Meets Primary Endpoint For NRAS-Mutant Melanoma. Dec 16, 2015 1267
Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate. Dec 15, 2015 770
Theravance Biopharma doses first patient in Phase 1 clinical trial of TD-1473. Dec 14, 2015 142
Theravance Biopharma doses first patient in Phase 1 clinical trial of TD-1473. Dec 14, 2015 138
Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction. Dec 10, 2015 961
CSL Behring Presents Phase III Data for Its Long-Acting Recombinant Factor IX Albumin Fusion Protein for Hemophilia B at the 57th ASH Annual Meeting & Exposition. Dec 7, 2015 1236
CEL-SCI admits 27 patients in November under ongoing Phase 3 trial of investigational immunotherapy Multikine for advanced primary squamous cell carcinoma of primary head and neck cancer. Dec 2, 2015 261
CEL-SCI admits 27 patients in November under ongoing Phase 3 trial of investigational immunotherapy Multikine for advanced primary squamous cell carcinoma of primary head and neck cancer. Dec 2, 2015 257
Canada : With PhIII trial coming up, Infinity strikes risk-based monitoring deal with Medidata. Dec 1, 2015 323
CTI BioPharma Announces United Kingdom National Cancer Research Institute AML Cooperative Group Advances Tosedostat to Next Stage of "Pick-a-Winner" LI-1 Trial for Older Patients with AML or High-Risk MDS. Clinical report Nov 24, 2015 1464
CTI BioPharma Announces Presentation of Preclinical Data Demonstrating Potential Synergistic Combination of Pacritinib and an EGFR Inhibitor in Targeting Brain Tumor Initiating Cells. Nov 23, 2015 1295
Array BioPharma signs cancer drug development agreement with Pierre Fabre. Nov 18, 2015 176
Array BioPharma signs cancer drug development agreement with Pierre Fabre. Nov 18, 2015 172
Profectus Presents Preclinical Data Demonstrating that a Single Dose of Multi-Component Vaccine Provides Complete Protection Against Zaire and Sudan Species of Ebola Virus and Marburg Virus. Nov 17, 2015 1006
US FDA grants approval for Genentech's melanoma drug. Nov 12, 2015 190
US FDA grants approval for Genentech's melanoma drug. Nov 12, 2015 186
Heraeus Medical and OrthoCyte partner to create bone-grafting therapies. Nov 1, 2015 545
Dr. Robert Pyke from S1 Biopharma to Present at ExL Pharma CNS Clinical Trial Forum. Oct 31, 2015 419
Gilead submits NDA to US FDA for once daily fixed-dose combination of sofosbuvir/velpatasvir for treating six genotypes of hepatitis C. Oct 29, 2015 260
Gilead submits NDA to US FDA for once daily fixed-dose combination of sofosbuvir/velpatasvir for treating six genotypes of hepatitis C. Oct 29, 2015 256
Japan : Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS (Brentuximab Vedotin) in Previously Untreated Advanced Hodgkin Lymphoma (HL). Oct 29, 2015 475
Sinovac Receives Clinical Trial Approval for Varicella Vaccine Candidate. Oct 26, 2015 1082
RegeneRx Updates on Asian Ophthalmic Clinical Trials. Oct 23, 2015 1208
RegeneRx Updates on U.S. Ophthalmic Clinical Trials. Oct 21, 2015 1103
Theravance Biopharma submits IND application to the US FDA to conduct first-in-human study of TD-0714 in cardiovascular and renal diseases. Oct 14, 2015 278
Theravance Biopharma submits IND application to the US FDA to conduct first-in-human study of TD-0714 in cardiovascular and renal diseases. Oct 14, 2015 274
RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial. Sep 30, 2015 949
Novavax Announces Positive Top-Line Data from Phase 2 Clinical Trial of RSV F Vaccine to Protect Infants via Maternal Immunization. Sep 29, 2015 1542
Preclinical Data on PL-3994 for Heart Failure and Resistant Hypertension Presented at 2015 Heart Failure Society of America Annual Meeting. Sep 28, 2015 794
CTI BioPharma to submit NDA to the US FDA for pacritinib for treating patients with myelofibrosis and low platelet counts. Sep 24, 2015 348
CTI BioPharma to submit NDA to the US FDA for pacritinib for treating patients with myelofibrosis and low platelet counts. Sep 24, 2015 352
CTI BioPharma To Submit NDA For Pacritinib In Q4 Based Primarily On Data From Single Pivotal Persist-1 Trial. Sep 23, 2015 1617
RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy (NK) Clinical Trial with RGN-259. Sep 21, 2015 1402
RegeneRx Announces First Patients Enrolled in Phase 2b/3 U.S. Dry Eye Clinical Trial with RGN-259. Sep 16, 2015 1306
Theravance Biopharma and Mylan Initiate Phase 3 Program for Revefenacin (TD-4208) for Treatment of Chronic Obstructive Pulmonary Disease (COPD). Sep 14, 2015 2255
Enteris BioPharma's Formulation Technology Enables Oral Delivery of Cara Therapeutics' CR845 Peptide in Phase 2 Trial in Osteoarthritis. Aug 20, 2015 540
Regen BioPharma Inc. Progresses in FDA Responses to dCellVax Clinical Trial Questions. Aug 10, 2015 689
Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults. Clinical report Aug 10, 2015 1832
RegeneRx Provides Update on Clinical Trials in U.S., Korea and China. Aug 6, 2015 981
CEL-SCI announces record July patient enrollment under its Phase 3 head and neck cancer trial. Aug 4, 2015 321
CEL-SCI announces record July patient enrollment under its Phase 3 head and neck cancer trial. Aug 4, 2015 317
Korea approves phase 2b/3 clinical trial in patients with Dry Eye syndrome. Aug 3, 2015 286
Korea approves phase 2b/3 clinical trial in patients with dry eye syndrome. Jul 27, 2015 287
Korea approves phase 2b/3 trial in patients with dry eye syndrome. Jul 27, 2015 287
Novavax reveals favorable top-line data from Phase I clinical trial of Ebola virus glycoprotein recombinant nanoparticle vaccine candidate. Jul 24, 2015 177
Novavax reveals favorable top-line data from Phase I clinical trial of Ebola virus glycoprotein recombinant nanoparticle vaccine candidate. Jul 24, 2015 173
MGB Biopharma Commences Phase I Clinical Trial With Oral Formulation of MGB-BP-3 for the Treatment of Multi-Resistant Clostridium Difficile Infections. Jul 21, 2015 766
MGB Biopharma Commences Phase I Clinical Trial With Oral Formulation of MGB-BP-3 for the Treatment of Multi-Resistant Clostridium Difficile Infections. Jul 21, 2015 771
RegeneRx Korean Licensee Receives Government Approval to Conduct Phase 2b/3 Clinical Trial in Patients with Dry Eye Syndrome. Jul 17, 2015 1129
Seattle Genetics starts a Phase II clinical trial of Adcetris. Jul 14, 2015 163
Seattle Genetics starts a Phase II clinical trial of Adcetris. Jul 14, 2015 159
Health Canada okays Phase 2 cervical spinal cord injury study. Jul 6, 2015 222
Semi-Permeable Films Pipeline Review 2015 Market Research Report. Jul 3, 2015 1224
Gilead Sciences submits NDA to the US FDA for once-daily single tablet regimen of emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) for HIV-1 infection. Jul 2, 2015 353
Gilead Sciences submits NDA to the US FDA for once-daily single tablet regimen of emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) for HIV-1 infection. Jul 2, 2015 349
Positive results from phase 1/2 dry AMD study. Jun 29, 2015 432
Health Canada okays Phase 2 cervical spinal cord injury study. Jun 29, 2015 221
Positive results from phase 1/2 dry AMD study. Jun 29, 2015 431
Health Canada okays Phase 2 cervical spinal cord injury study. Jun 29, 2015 221
Helix BioPharma starts patient enrolment for thirteenth dose level group in Polish Phase I/II trial of L-DOS47. Jun 24, 2015 223
Helix BioPharma starts patient enrolment for thirteenth dose level group in Polish Phase I/II trial of L-DOS47. Jun 24, 2015 219
Cancer Clinical Trials Expert Dr. Santosh Kesari to Assist Regen BioPharma, Inc. in Addressing FDA Questions Regarding Planned dCellVax Immunotherapy Clinical Trial for Breast Cancer. Jun 10, 2015 601
Braeburn Pharmaceuticals Reports Positive Results From Phase 3 Study Of Probuphine For Opioid Addiction. Clinical report Jun 8, 2015 1910
Pharming Announces Interim Results From the Ongoing Phase II Pediatric Clinical Trial of RUCONEST. Jun 1, 2015 1430
Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology. Clinical report May 22, 2015 1159
Benitec Biopharma Doses Fifth Patient And Initiates Additional Trial Site For Hepatitis C Trial. Apr 29, 2015 835
CryoLife Announces Enrollment of First Patient in PerClot IDE Clinical Trial. Apr 28, 2015 1144
CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be Presented in Late-Breaking Session at ASCO. Apr 22, 2015 1742
RegeneRx Biopharmaceuticals' US JV retains Ora to conduct Phase III trial of RGN-259/GBT201. Apr 21, 2015 173
RegeneRx Biopharmaceuticals' US JV retains Ora to conduct Phase III trial of RGN-259/GBT201. Apr 21, 2015 169
RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. Apr 16, 2015 1446
RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea. Apr 1, 2015 768
Biogen Idec reports positive interim results from Phase Ib PRIME trial of aducanumab. Mar 24, 2015 175
Biogen Idec reports positive interim results from Phase Ib PRIME trial of aducanumab. Mar 24, 2015 171
CTI BioPharma Announces Publication In Blood Of Phase 2 Results Of Pacritinib In Patients With Myelofibrosis. Clinical report Mar 16, 2015 1937
Benitec Biopharma Doses Fourth Patient In Hepatitis C Trial. Mar 11, 2015 689
CTI BioPharma And Baxter Announce Positive Top-Line Results From Phase 3 Persist-1 Trial Of Pacritinib For Patients With Myelofibrosis. Financial report Mar 9, 2015 2745
First Patient Treated In Trial Of Matrix For Lipoatrophy. Mar 9, 2015 177
Theravance Biopharma collaborates with Mylan to develop and commercialise TD-4208. Feb 4, 2015 154
Theravance Biopharma collaborates with Mylan to develop and commercialise TD-4208. Feb 4, 2015 150
RegeneRx Biopharmaceuticals signs contracts with G-treeBNT. Jan 30, 2015 169
RegeneRx Biopharmaceuticals signs contracts with G-treeBNT. Jan 30, 2015 165
Steatohepatitis Therapeutics Clinical Trials Market H1 2015 Review Report at RnRMarketResearch.com. Jan 30, 2015 1022
Synageva BioPharma starts dosing in Phase I/II trial with SBC-103. Jan 28, 2015 206
Synageva BioPharma starts dosing in Phase I/II trial with SBC-103. Jan 28, 2015 202
RegeneRx and G-treeBNT Create Joint Venture to Develop RGN-259 in the U.S. Jan 28, 2015 1031
WCCT Global signs clinical trial partnership with Dynport Vaccine. Jan 26, 2015 118
WCCT Global signs clinical trial partnership with Dynport Vaccine. Jan 26, 2015 114
Canada : Health Canada Clears Immunovaccine to Conduct Phase I Clinical Trial of Respiratory Syncytial Virus (RSV) Vaccine. Jan 22, 2015 440
BioInvent's Bi-1206 antibody to enter Collaborative Phase L/Ll Trial for CLL and NHL patients. Jan 20, 2015 437
BioInvent's Bi-1206 antibody to enter Collaborative Phase L/Ll Trial for CLL and NHL patients. Jan 20, 2015 433
G-treeBNT files IND for a Phase IIB/III clinical trial with RGN-259. Dec 30, 2014 195
G-treeBNT files IND for a Phase IIB/III clinical trial with RGN-259. Dec 30, 2014 191
Palatin Announces Start of Bremelanotide Phase 3 Program For Female Sexual Dysfunction. Dec 29, 2014 1237
RegeneRx Partner Submits Phase IIB/III IND to Korean Health Authority for RGN-259 for the Treatment of Dry Eye Syndrome. Dec 29, 2014 1037
Cerus' Intercept Meets Endpoint in Phase 2 Clinical Trial. Dec 22, 2014 297
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis (Carfilzomib) In Patients With Relapsed Multiple Myeloma. Clinical report Dec 6, 2014 3715
MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting. Dec 6, 2014 1534
Galena Biopharma completes patient enrollment in GALE-401 Phase II clinical trial. Nov 20, 2014 121
Galena Biopharma completes patient enrollment in GALE-401 Phase II clinical trial. Nov 20, 2014 117
MorphoSys receives fast track designation for MOR208 from US Food and Drug Administration. Nov 11, 2014 187
Synageva BioPharma Presents New Data From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency At The AASLD Meeting. Nov 10, 2014 2331
Clinical trials of 2 Ebola vaccines starts,results will be available in December. Oct 25, 2014 691
Vaxart to commence human clinical trials of Ebola tablet vaccine in early 2105. Oct 23, 2014 302
Vaxart to commence human clinical trials of Ebola tablet vaccine in early 2105. Oct 23, 2014 298
Sutro Biopharma, Celgene join forces to discover, develop antibodies, ADCs. Oct 23, 2014 364
RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy. Oct 20, 2014 1363
CIRM grant will fund phase l/2a clinical trial stem cell SCI treatment. Oct 20, 2014 353
CIRM grant will fund phase 1/2a clinical trial of stem cell so treatment. Oct 20, 2014 353
MabVax Therapeutics Receives Orphan Drug Designation for Therapeutic Vaccine to Treat Childhood Cancer Neuroblastoma. Sep 25, 2014 991
Inovio Pharmaceuticals Ebola Vaccine Moving into Human Trial with GeneOne Life Science. Sep 24, 2014 1272
Sutro Biopharma, Merck KGaA to jointly develop antibody drug conjugates. Sep 17, 2014 258
Asterias Biotherapeutics begins next phase of cervical SCI trial. Sep 1, 2014 439
Traumatic Spinal Cord Injury Global Clinical Trials Review, H2, 2014. Aug 25, 2014 1735
Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck. Aug 20, 2014 1662
United States : Amgen Announces Top-line Results from Phase 3 FOCUS Trail of KYPROLIS in Patients with Relapsed and Advanced Refractory Multiple Myeloma. Financial report Aug 14, 2014 241
Amgen Announces Top-Line Results From Phase 3 Focus Trial Of Kyprolis In Patients With Relapsed And Advanced Refractory Multiple Myeloma. Aug 13, 2014 2559
Spinal Cord Injury Global Clinical Trials Review, H2, 2014. Aug 11, 2014 2032
Multiple Sclerosis Global Clinical Trials Review, H2, 2014. Aug 5, 2014 1966
Muscle Spasticity Global Clinical Trials Review, H2, 2014. Aug 5, 2014 1914
United Kingdom : Amgen Announces Phase 3 ASPIRE Trial of Kyprolis in Patients with Relapsed Multiple Myeloma Met Primary Endpoint. Aug 5, 2014 111
Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis In Patients With Relapsed Multiple Myeloma Met Primary Endpoint. Aug 4, 2014 2864
Incyte signs clinical trial agreement with Genentech. Aug 1, 2014 149
Incyte signs clinical trial agreement with Genentech. Aug 1, 2014 145

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters